Celcuity Inc. (NASDAQ:CELC) Receives Average Recommendation of "Buy" from Analysts

Celcuity Inc. (NASDAQ:CELC - Get Free Report) has received an average recommendation of "Buy" from the seven brokerages that are currently covering the firm, MarketBeat.com reports. Six investment analysts have rated the stock with a buy rating and one has given a strong buy rating to the company. The average 12 month price objective among brokerages that have issued ratings on the stock in the last year is $30.17.

Several equities analysts have weighed in on the company. HC Wainwright reissued a "buy" rating and set a $27.00 price objective on shares of Celcuity in a report on Tuesday. Needham & Company LLC reaffirmed a "buy" rating and set a $29.00 price objective on shares of Celcuity in a report on Tuesday.

Celcuity Stock Performance

Shares of Celcuity stock traded down $0.32 during trading hours on Friday, hitting $9.04. 53,514 shares of the company's stock traded hands, compared to its average volume of 267,583. The company has a fifty day simple moving average of $11.10 and a 200-day simple moving average of $12.84. The company has a debt-to-equity ratio of 0.65, a current ratio of 10.35 and a quick ratio of 10.36. The stock has a market capitalization of $335.66 million, a price-to-earnings ratio of -3.46 and a beta of 0.44. Celcuity has a 12-month low of $8.50 and a 12-month high of $20.89.

Celcuity (NASDAQ:CELC - Get Free Report) last released its earnings results on Monday, March 31st. The company reported ($0.85) earnings per share for the quarter, missing analysts' consensus estimates of ($0.72) by ($0.13). Equities research analysts anticipate that Celcuity will post -2.62 EPS for the current fiscal year.

Institutional Inflows and Outflows

Several large investors have recently added to or reduced their stakes in CELC. Charles Schwab Investment Management Inc. lifted its holdings in shares of Celcuity by 226.2% in the third quarter. Charles Schwab Investment Management Inc. now owns 221,671 shares of the company's stock worth $3,305,000 after buying an additional 153,712 shares in the last quarter. BNP Paribas Financial Markets lifted its stake in Celcuity by 2,083.4% in the 3rd quarter. BNP Paribas Financial Markets now owns 45,110 shares of the company's stock worth $673,000 after purchasing an additional 43,044 shares in the last quarter. State Street Corp boosted its holdings in Celcuity by 152.2% in the 3rd quarter. State Street Corp now owns 1,107,415 shares of the company's stock valued at $16,512,000 after purchasing an additional 668,318 shares during the period. Wellington Management Group LLP purchased a new position in shares of Celcuity during the 3rd quarter valued at $770,000. Finally, XTX Topco Ltd purchased a new position in shares of Celcuity during the 3rd quarter valued at $307,000. Institutional investors own 63.33% of the company's stock.

Celcuity Company Profile

Celcuity Inc, a clinical stage biotechnology company, focuses on the development of targeted therapies for the treatment of various solid tumors in the United States. The company's CELsignia diagnostic platform uses a patient's living tumor cells to identify the specific abnormal cellular process driving a patient's cancer and the related targeted therapy for the treatment.